causal

Value-free pricing stifles rather than spurs innovation

Because a company can command a high price regardless of value, the rational strategy is to make low-risk 'me-too' drugs—slightly modifying an existing drug to win a new patent and capture the market for another 7-10 years—rather than risk a genuine breakthrough; many blockbusters come from buying small innovative firms rather than in-house innovation, so tying price to value would actually increase innovation by rewarding real risk-taking.

causalpending

Speaker

Vincent Rajkumar

Evidence Quote

“It actually stifles innovation, because: Why innovate and take a big risk when you can just modify your existing drug and capture the whole market for another 7-10 years?”

Source

Vincent Rajkumar on the High Price of Cancer Drugs— EconTalk
Created: 6/13/2026, 12:13:30 AM

Your notes

Loading notes...